Albany, NY -- (SBWIRE) -- 03/01/2018 -- The U.S. and China market for asthma and COPS drugs is anticipated to showcase a steep trajectory for growth in the coming years. According to a report by Transparency Market Research (TMR), the leading companies in the U.S. and China asthma and COPD drugs market accounted for just under 64.0% in 2015, demonstrating the consolidated nature of this industry, along with high levels of competition among the established players. Merck & Co. Inc., Novartis AG, Astrazeneca plc, GlaxoSmithKline plc and Boehringer Ingelheim are currently among the leading names in the market.

According to the report, the market is slated to ascend from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by the end of 2024. On the off chance that these numbers remain constant, the market is expected to exhibit a healthy 4.1% CAGR over the forecast period.

Read Report Overview: https://www.transparencymarketresearch.com/us-china-asthma-copd-drugs-market.html

Combination Drugs Segment to Emerge as Leading Segment Due to High Demand

Based on the different classes of drugs in the U.S. & China, the report bifurcates the future extent of development for assortments, for instance anti-inflammatory drugs, bronchodilators, combination drugs and monoclonal antibodies.

Of these, the fragment of combination drugs is directly the leading market segment in the coming years. It represented a 54% of the U.S. and China asthma and COPD drugs market in 2015 and is relied upon to keep on dominating all through forecast duration. Combination drugs advantage from the suggestions from organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Global Initiative for Asthma (GINA), which see blend sedates as the more secure course of overseeing asthma and COPD. The rise of new medication applicants in this section will reinforce its development potential in the market over the years to come.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=15857

Govt Support to Offer Lucrative Market Opportunity

Asthma and COPD are two maladies encountering expanding pervasiveness comprehensively because of a mix of variables, including the maturing populace and the rising contamination levels, especially in rising nations. COPD is one of the best five reasons for inability and demise in industrialized nations and the fourth-driving reason for deaths over the world. The utilization of medications has risen as a successful answer for the treatment of COPD and asthma, which will lead to high market opportunity. The market is driven by the developing patient COPD and asthmatic populace, and also FDA endorsements for the novel items and its wide acknowledgment among the patient populace. Expanding government activities to control COPD and asthma additionally fuel the development for this market. Increment in presentation of non-specific medications, and rising predominance of asthma combined with geriatric populace and lifestyle changes are the main considerations that credit to the ascent in growth of this market.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=15857

About Transparency Market Research
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/